Indication
POEMS syndrome
2 clinical trials
5 products
Clinical trial
Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS SyndromeStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Product
DexamethasoneProduct
IxazomibProduct
LenalidomideClinical trial
An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment of Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemStatus: Recruiting, Estimated PCD: 2027-02-22
Product
CT103A